Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Please delete Claims 1-47. Add the following claims 48-74.

Listing of Claims:

1-47. (deleted)

48. (new) A compound of the following formula:



wherein

R_4 is selected from the group consisting of:

C_{1-8}alkyl, which is optionally substituted on a terminal carbon with a substituent selected from the group consisting of -C(O)H, -C(O)(C_{1-8})alkyl, -CO_2H, -CO_2(C_{1-8})alkyl, amino, amino substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-8}alkyl, cyano, (halo)$_{1-3}$, hydroxy, nitro, cycloalkyl, aryl, thienyl, imidazolinyl, and triazolyl;

C_{1-8}alkoxy or C_{1-8}alkoxy substituted on a terminal carbon with a substituent selected from the group consisting of (halo)$_{1-3}$ and hydroxy;

-C(O)H, -C(O)(C_{1-8})alkyl, -CO_2H, -CO_2(C_{1-8})alkyl;

amino, or amino substituted with two substituents independently selected from the group consisting of C_{1-8}alkyl and -SO_2-(C_{1-8})alkyl;

-C(O)amino, wherein amino is substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-8}alkyl;

-SO_2- ,substituted with one substituent selected from the group consisting of thienyl, imidazolinyl, triazolyl and amino, wherein amino is substituted with two

substituents independently selected from the group consisting of hydrogen, C_{1-8}alkyl, -C_{1-8}alkylamino, wherein amino is substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-8}alkyl, thienyl, imidazolinyl, and triazolyl;

cycloalkyl, aryl, thienyl, imidazolinyl, and triazolyl;

wherein cycloalkyl, aryl, thienyl, imidazolinyl, and triazolyl are optionally substituted with 1 to 3 substituents independently selected from the group consisting of C_{1-8}alkyl, wherein alkyl is optionally substituted on a terminal carbon with a substituent selected from the group consisting of amino, or amino substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-8}alkyl, cyano, $(halo)_{1-3}$, hydroxy and nitro, C_{1-8}alkoxy, amino, substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-8}alkyl), cyano, halo, hydroxy and nitro; and, wherein thienyl, imidazolinyl, or triazolyl are optionally substituted with 1 to 2 oxo substituents;

X is selected from the group consisting of –C(O)-, -C(S)- and -SO_2-; and,

R_3 is selected from the group consisting of:

C_{1-8}alkyl, C_{2-8}alkenyl, C_{2-8}alkynyl, wherein alkyl, alkenyl and alkynyl are optionally substituted on a terminal carbon with a substituent selected from the group consisting of -C(O)H, -C(O)(C_{1-8})alkyl, -CO_2H, -CO_2(C_{1-8})alkyl, amino or amino substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-8}alkyl, cyano, $(halo)_{1-3}$, hydroxy, nitro, aryl and thienyl, imidazolinyl, or triazolyl; wherein aryl, thienyl, imidazolinyl, or triazolyl are optionally substituted with 1 to 3 substituents independently selected from the group consisting of C_{1-8}alkyl, cyano, halo, $(halo)_{1-3}$(C_{1-8})alkyl, $(halo)_{1-3}$(C_{1-8})alkoxy, hydroxy, hydroxy(C_{1-8})alkyl, hydroxy(C_{1-8})alkoxy and nitro;

cycloalkyl, thienyl, imidazolinyl, triazolyl, and aryl, wherein cycloalkyl, thienyl, imidazolinyl, triazolyl, and aryl are optionally substituted with 1 to 3 substituents independently selected from the group consisting of cyano, halo, hydroxy and

nitro; and, wherein cycloalkyl, aryl, thienyl, imidazolinyl, or triazolyl are optionally substituted with 1 to 2 substituents independently selected from the group consisting of:

C_{1-8}alkyl, C_{2-8}alkenyl, wherein alkyl and alkenyl are optionally substituted on a terminal carbon with a substituent selected from the group consisting of -C(O)H, -C(O)(C_{1-8})alkyl, -CO_2H, -CO_2(C_{1-8})alkyl, amino, amino substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-8}alkyl, cyano, (halo)$_{1-3}$, hydroxy, nitro, cycloalkyl, thienyl, imidazolinyl, triazolyl, and aryl,

-CH(OH)-(C_{1-8})alkyl,

C_{1-8}alkoxy, optionally substituted on a terminal carbon with a substituent selected from the group consisting of (halo)$_{1-3}$ and hydroxy;

-C(O)H, -C(O)(C_{1-8})alkyl, -CO_2H, -CO_2(C_{1-8})alkyl,

amino, or amino substituted with two substituents independently selected from the group consisting of hydrogen, C_{1-8}alkyl and -C(O)(C_{1-8})alkyl,

-C(O)amino, wherein amino is substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-8}alkyl,

-SO_2-, substituted with one substituent selected from the group consisting of thienyl, imidazolinyl, triazolyl and amino, wherein amino is substituted with two substituents independently selected from the group consisting of hydrogen, C_{1-8}alkyl and -C_{1-8}alkylamino, wherein amino is substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-8}alkyl;

-NH-SO_2-(C_{1-8})alkyl,

cycloalkyl, thienyl, imidazolinyl, triazolyl, optionally substituted with 1 to 2 oxo substituents, aryl, thienyl, imidazolinyl, and triazolyl;

and pharmaceutically acceptable salts thereof.

49. (new) A compound of the following formula:



wherein

R_4 is selected from the group consisting of:

amino, and amino substituted with two substituents independently selected from the group consisting of hydrogen, C_{1-4}alkyl and $-SO_2-(C_{1-4})$alkyl);

$-SO_2-$, substituted with one substituent selected from the group consisting of amino, or amino substituted with two substituents independently selected from the group consisting of hydrogen, C_{1-4}alkyl, $-C_{1-4}$alkylamino, wherein $-C_{1-4}$alkylamino is substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-4}alkyl;

X is selected from the group consisting of –C(O)-, -C(S)- and $-SO_2-$;

and R_3 is selected from the group consisting of:

C_{1-8}alkyl, C_{2-8}alkenyl, C_{2-8}alkynyl, wherein alkyl, alkenyl and alkynyl are optionally substituted on a terminal carbon with a substituent selected from the group consisting of -C(O)H, $-C(O)(C_{1-8})$alkyl, $-CO_2H$, $-CO_2(C_{1-8})$alkyl, amino or amino substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-8}alkyl, cyano, $(halo)_{1-3}$, hydroxy, nitro, aryl and thienyl, imidazolinyl, or triazolyl; wherein aryl, thienyl, imidazolinyl, or triazolyl are optionally substituted with 1 to 3 substituents independently selected from the group consisting of C_{1-8}alkyl, cyano, halo, $(halo)_{1-3}(C_{1-8})$alkyl, $(halo)_{1-3}(C_{1-8})$alkoxy, hydroxy, hydroxy(C_{1-8})alkyl, hydroxy(C_{1-8})alkoxy and nitro;

cycloalkyl, thienyl, imidazolinyl, triazolyl, and aryl, wherein cycloalkyl, thienyl, imidazolinyl, triazolyl, and aryl are optionally substituted with 1 to 3 substituents independently selected from the group consisting of cyano, halo, hydroxy and nitro; and, wherein cycloalkyl, aryl, thienyl, imidazolinyl, or triazolyl are optionally

substituted with 1 to 2 substituents independently selected from the group consisting of:

C_{1-8}alkyl, C_{2-8}alkenyl, wherein alkyl and alkenyl are optionally substituted on a terminal carbon with a substituent selected from the group consisting of -C(O)H, -C(O)(C_{1-8})alkyl, -CO_2H, -CO_2(C_{1-8})alkyl, amino, amino substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-8}alkyl, cyano, (halo)$_{1-3}$, hydroxy, nitro, cycloalkyl, thienyl, imidazolinyl, triazolyl, and aryl,

-CH(OH)-(C_{1-8})alkyl,

C_{1-8}alkoxy, optionally substituted on a terminal carbon with a substituent selected from the group consisting of (halo)$_{1-3}$ and hydroxy;

-C(O)H, -C(O)(C_{1-8})alkyl, -CO_2H, -CO_2(C_{1-8})alkyl,

amino, or amino substituted with two substituents independently selected from the group consisting of hydrogen, C_{1-8}alkyl and -C(O)(C_{1-8})alkyl,

-C(O)amino, wherein amino is substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-8}alkyl,

-SO_2-, substituted with one substituent selected from the group consisting of thienyl, imidazolinyl, triazolyl and amino, wherein amino is substituted with two substituents independently selected from the group consisting of hydrogen, C_{1-8}alkyl and -C_{1-8}alkylamino, wherein amino is substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-8}alkyl;

-NH-SO_2-(C_{1-8})alkyl,

cycloalkyl, thienyl, imidazolinyl, triazolyl, optionally substituted with 1 to 2 oxo substituents, aryl, thienyl, imidazolinyl, and triazolyl;

and pharmaceutically acceptable salts thereof.

50. (new) A compound of the following formula :



wherein

R_4 is selected from the group consisting of:

-SO_2- ,substituted with one substituent selected from the group consisting of thienyl, imidazolinyl, triazolyl and amino, wherein amino is substituted with two substituents independently selected from the group consisting of hydrogen, C_{1-8}alkyl, -C_{1-8}alkylamino, wherein -C_{1-8}alkylamino is substituted with two substituents independently selected from the group consisting of hydrogen and C_{1-8}alkyl, thienyl, imidazolinyl, and triazolyl; and

X is selected from the group consisting of –C(O)-, -C(S)- and -SO_2-;

R_3 is selected from the group consisting of:

C_{1-8}alkyl, C_{2-8}alkenyl, C_{2-8}alkynyl, cycloalkyl, thienyl, imidazolinyl, triazolyl, and phenyl;

wherein the C_{1-8}alkyl, C_{2-8}alkenyl, C_{2-8}alkynyl, cycloalkyl, thienyl, imidazolinyl, triazolyl, and phenyl substituents are optionally substituted with 1 to 3 substituents independently selected from the group consisting of C_{1-8}alkyl, C_{1-8} alkyl(mono-, di- or tri-halo), C_{1-8} alkoxy, cyano, halo, hydroxy and nitro -C(O)(C_{1-8})alkyl and -CH(OH)(C_{1-8})alkyl;

and pharmaceutically acceptable salts thereof.

51. (new) The compound of claim 50 wherein X, R_3 and R_4 are dependently selected from the group consisting of:

X	R_3	R_4
C(O)	(2,6-F_2)Ph	4-SO_2-NH_2;
C(O)	(2,6-F_2-3-CH_3)Ph	4-SO_2-NH_2;
C(O)	(2,4,6-F_3)Ph	4-SO_2-NH_2;
C(O)	(2-F)Ph	4-SO_2-NH_2;
C(O)	(2,4-F_2)Ph	4-SO_2-NH_2;
C(O)	(2-F-6-CF_3)Ph	4-SO_2-NH_2;
C(O)	(2,6-Cl_2)Ph	4-SO_2-NH_2;
C(O)	(2,4,6-Cl_3)Ph	4-SO_2-NH_2;
C(O)	(2-NO_2)Ph	4-SO_2-NH_2;
C(O)	[2,6-(OCH_3)$_2$]Ph	4-SO_2-NH_2;
C(O)	[2,4,6-(CH_3)$_3$]Ph	4-SO_2-NH_2;
C(O)	Ph	4-SO_2-NH_2;
C(O)	2-thienyl	4-SO_2-NH_2;
C(O)	(3-CH_3)2-thienyl	4-SO_2-NH_2;
C(O)	(3-F)2-thienyl	4-SO_2-NH_2;
C(O)	(3-Cl)2-thienyl	4-SO_2-NH_2;
C(O)	(3-OCH_2CH_3)2-thienyl	4-SO_2-NH_2;
C(O)	(3-$NHCOCH_3$)2-thienyl	4-SO_2-NH_2;
C(O)	(5-CH_3)2-thienyl	4-SO_2-NH_2;
C(O)	(5-Br)2-thienyl	4-SO_2-NH_2;
C(O)	(5-$COCH_3$)2-thienyl	4-SO_2-NH_2;

C(O)	3-thienyl	4-SO_2-NH_2;
C(O)	3a,7a-dihydrobenzo[*b*]thien-2-yl	4-SO_2-NH_2;
C(O)	(5–CH_2CH_3)2-thienyl	4-SO_2-NH_2;
C(O)	[3,5–$(CH_3)_2$]2-thienyl	4-SO_2-NH_2;
C(O)	(3-Br)2-thienyl	4-SO_2-NH_2;
C(O)	1,2,3-thiadiazol-4-yl	4-SO_2-NH_2;
C(O)	Cyclopentyl	4-SO_2-NH_2;
C(O)	Cyclohexyl	4-SO_2-NH_2;
C(O)	2-thienyl-CH_2	4-SO_2-NH_2;
C(O)	2-thienyl-$(CH)_2$	4-SO_2-NH_2;
C(O)	(2,6-F_2)-Ph-CH_2	4-SO_2-NH_2;
C(O)	(2,6-F_2)Ph$(CH)_2$	4-SO_2-NH_2;
C(O)	Cycloheptyl	4-SO_2-NH_2;
C(O)	4-CH_3-cyclohexyl	4-SO_2-NH_2;
C(O)	4-CH_3-cyclohexyl	4-SO_2-NH_2;
C(O)	4-$(CH_2)_3CH_3$-cyclohexyl	4-SO_2-NH_2;
C(O)	5-(2-pyridinyl)2-thienyl	4-SO_2-NH_2;
C(O)	3-(1*H*-pyrrol-1-yl)2-thienyl	4-SO_2-NH_2;
C(O)	5-[$C(CH_3)_3$]2-thienyl	4-SO_2-NH_2;
C(O)	5-[$(CH)_2C(O)OC(CH_3)_3$]2-thienyl	4-SO_2-NH_2;
C(O)	$Ph(C)_2$	4-SO_2-NH_2;

C(O)	(2,6-F_2-3-NO_2)Ph	4-SO_2-NH_2;
C(O)	(2,6-F_2-3-NH_2)Ph	4-SO_2-NH_2;
C(O)	[2,6-$(CH_3)_2$]Ph	4-SO_2-NH_2;
C(O)	(2-CH_3)Ph	4-SO_2-NH_2;
C(O)	[2,6-F_2-3-CH(OH)CH_3]Ph	4-SO_2-NH_2;
C(O)	(2,6-F_2)Ph	4-SO_2-NH_2;
C(O)	(2,6-F_2-3-CH_3)Ph	4-SO_2-NH_2;
C(S)	-NH[(2,6-F_2)Ph]	4-SO_2-NH_2;
C(O)	-NH[(2,6-F_2)Ph]	4-SO_2-NH_2;
SO_2	(2,6-F_2)Ph	4-SO_2-NH_2;
C(O)	(2-Cl-3-CH_3-6-F)Ph	4-SO_2-NH_2;
C(O)	(2-Cl-6-F)Ph	4-SO_2-NH_2; and
C(O)	(2,6-F_2-5-Cl)Ph	4-SO_2-NH_2.

52. (new) The compound of claim 50 wherein X, R_3 and R_4 are dependently selected from the group consisting of:

X	**R_3**	**R_4**
C(O)	(2,6-F_2)Ph	4-SO_2-NH_2;
C(O)	(2,6-F_2-3-CH_3)Ph	4-SO_2-NH_2;
and,		
C(S)	-NH[(2,6-F_2)Ph]	4-SO_2-NH_2.

53. (new) (new) The compound of claim 50 which is selected from the group consisting of:

5-amino-3-[[4-(aminosulfonyl)phenyl]amino]-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carbothioamide;

5-amino-3-[[4-(aminosulfonyl)phenyl]amino]-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carboxamide;

4-[[5-amino-1-(2-chloro-6-fluoro-3-methylbenzoyl)-1H-1,2,4-triazol-3-yl]amino]-benzenesulfonamide;

4-[[5-amino-1-(2-chloro-6-fluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]-benzenesulfonamide;

4-[[5-amino-1-(2,6-difluoro-3-methylbenzoyl)-1*H*-1,2,4-triazol-3-yl]amino]-*N*-methyl-benzenesulfonamide;

4-[[5-amino-1-[(3-methyl-2-thienyl)carbonyl]-1*H*-1,2,4-triazol-3-yl]amino]-*N*-methyl-benzenesulfonamide;

4-[[5-amino-1-[(3-methyl-2-thienyl)carbonyl]-1*H*-1,2,4-triazol-3-yl]amino]-*N*-[2-(dimethylamino)ethyl]-benzenesulfonamide;

1-[4-[[5-amino-1-[(3-methyl-2-thienyl)carbonyl]-1*H*-1,2,4-triazol-3-yl]amino]phenyl]-2-imidazolidinone;

54. (new) The compound of claim 50 wherein X, R_3 and R_4 are dependently selected from the group consisting of:

X	**R_3**	**R_4**
C(O)	(2,6-F_2)Ph	4-SO_2-NH(CH_2CH_3);
C(O)	(2,6-F_2)Ph	4-SO_2-NH(CH_3);
C(O)	(2,6-F_2-3-CH_3)Ph	4-SO_2-NH(CH_3);
C(O)	(3–CH_3)2-thienyl	4-SO_2-NH(CH_3);
C(O)	[3,5–(CH_3)$_2$]2-thienyl	4-SO_2-NH(CH_3);
C(O)	(5–CH_2CH_3)2-thienyl	4-SO_2-NH(CH_3);
C(O)	[3,5–(CH_3)$_2$]2-thienyl	4-SO_2-N(CH_3)$_2$;
C(O)	(5–CH_2CH_3)2-thienyl	4-SO_2-N(CH_3)$_2$;
C(O)	(3–CH_3)2-thienyl	4-SO_2-N(CH_3)$_2$;
C(O)	(2,6-F_2-3-CH_3)Ph	4-SO_2-N(CH_3)$_2$; and
C(O)	(2,6-F_2)Ph	4-SO_2-N(CH_3)$_2$.

55. (new) The compound of claim 50 wherein X, R_3 and R_4 are dependently selected from the group consisting of:

X	R_3	R_4
C(O)	(2,6-F_2-3-CH_3)Ph	4-(1-*H*-1,2,4-triazol-1-yl);
C(O)	(2,6-F_2)Ph	4-(1-*H*-1,2,4-triazol-1-yl);
C(O)	(5–CH_2CH_3)2-thienyl	4-(1-*H*-1,2,4-triazol-1-yl);
C(O)	[3,5–(CH_3)$_2$]2-thienyl	4-(1-*H*-1,2,4-triazol-1-yl);
C(O)	(3–CH_3)2-thienyl	4-(1-*H*-1,2,4-triazol-1-yl);
C(O)	(2,6-F_2)Ph	4-(1-*H*-1,3,4-triazol-1-yl);
C(O)	(2,6-F_2-3-CH_3)Ph	4-(1-*H*-1,3,4-triazol-1-yl); and
C(O)	(3–CH_3)2-thienyl	4-(1-*H*-1,3,4-triazol-1-yl).

56. (new) The compound of claim 50 wherein X, R_3 and R_4 are dependently selected from the group consisting of:

X	R_3	R_4
C(O)	(2,6-F_2-3-CH_3)Ph	4-(1-*H*-1,2,4-triazol-1-yl);
C(O)	(2,6-F_2)Ph	4-(1-*H*-1,2,4-triazol-1-yl);
C(O)	(5–CH_2CH_3)2-thienyl	4-(1-*H*-1,2,4-triazol-1-yl);
C(O)	[3,5–(CH_3)$_2$]2-thienyl	4-(1-*H*-1,2,4-triazol-1-yl);
C(O)	(3–CH_3)2-thienyl	4-(1-*H*-1,2,4-triazol-1-yl);
C(O)	(2,6-F_2)Ph	4-(1-*H*-1,3,4-triazol-1-yl);
C(O)	(2,6-F_2-3-CH_3)Ph	4-(1-*H*-1,3,4-triazol-1-yl);
C(O)	(3–CH_3)2-thienyl	4-(1-*H*-1,3,4-triazol-1-yl);

57. (new) The compound of claim 50 wherein X, R_3 and R_4 are dependently selected from the group consisting of:

X	**R_3**	**R_4**
C(O)	(5–CH_2CH_3)2-thienyl	4-SO_2-NH[$(CH_2)_2N(CH_3)_2$];
C(O)	(3–CH_3)2-thienyl	4-SO_2-NH[$(CH_2)_2N(CH_3)_2$];
C(O)	(2,6-F_2-3-CH_3)Ph	4-SO_2-NH[$(CH_2)_2N(CH_3)_2$];
C(O)	(2,6-F_2)Ph	4-SO_2-NH[$(CH_2)_2N(CH_3)_2$];
C(O)	[3,5–$(CH_3)_2$]2-thienyl	4-SO_2-NH[$(CH_2)_2N(CH_3)_2$];
C(O)	[3,5–$(CH_3)_2$]2-thienyl	4-NH-SO_2-CH_3;
C(O)	(3–CH_3)2-thienyl	4-NH-SO_2-CH_3;
C(O)	(5–CH_2CH_3)2-thienyl	4-NH-SO_2-CH_3;
C(O)	(2,6-F_2)Ph	4-NH-SO_2-CH_3; and
C(O)	(2,6-F_2-3-CH_3)Ph	4-NH-SO_2-CH_3.

58. (new) A pharmaceutical composition comprising a compound of claim 48 and a pharmaceutically acceptable carrier.

59. (new) A pharmaceutical composition made by mixing a compound of claim 48 and a pharmaceutically acceptable carrier.

60. (new) A method for preparing a pharmaceutical composition comprising mixing a compound of claim 48 and a pharmaceutically acceptable carrier.

61. (new) A method for treating or ameliorating a kinase mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 48.

62. (new) The method of claim 61 wherein the disorder is mediated by selective inhibition of a kinase selected from the group consisting of a cyclin dependent kinase and a tyrosine kinase.

63. (new) The method of claim 62 wherein the kinase is selected from the group consisting of cyclin dependent kinase-1, cyclin dependent kinase-2, cyclin dependent kinase-4, vascular endothelial growth factor receptor-2, endothelial growth factor receptor and human epidermal growth factor receptor-2.

64. (new) The method of claim 61 wherein the disorder is mediated by dual inhibition of at least two kinases selected from the group consisting of a cyclin dependent kinase and a tyrosine kinase.

65. (new) The method of claim 64 wherein at least two kinases are selected from the group consisting of cyclin dependent kinase-1, cyclin dependent kinase-2, cyclin dependent kinase-4, vascular endothelial growth factor receptor-2, endothelial growth factor receptor and human epidermal growth factor receptor-2.

66. (new) The method of claim 61 wherein the therapeutically effective amount of the compound of claim 48 is from about 0.001 mg/kg/day to about 300 mg/kg/day.

67. (new) The method of claim 61 wherein the kinase mediated disorder is selected from the group consisting of cancer and tumor growth, tumor vascularization, angiopathy, angiogenesis, chemotherapy-induced alopecia and restenosis.

68. (new) The method of claim 61 further comprising a method for using a compound of claim 48 as an adjunct to chemotherapy and radiation therapy.

69. (new) The method of claim 61 further comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 58.

70. (new) The method of claim 69 wherein the therapeutically effective amount of a pharmaceutical composition of claim 58 is from about 0.001 mg/kg/day to about 300 mg/kg/day.

71. (new) The method of claim 61 further comprising administering to a subject in need thereof a therapeutically effective amount of at least one other agent in combination with a compound of claim 48.

72. (new) The method of claim 71 wherein the at least one other agent is a chemotherapeutic agent to treat cancer.

73. (new) The method of claim 72 wherein the dose of the chemotherapeutic agent is reduced relative to the dose that would be given in the absence of the therapeutically effective amount of the compound of claim 48.

74. (new) The method of claim 72 wherein the therapeutically effective amount of a compound of claim 48 is given to the subject before, during or after the chemotherapeutic agent.